Novartis’ Phase 3 cholesterol study fails key cardiovascular goal
Novartis said a highly anticipated cholesterol drug failed in a Phase 3 study to reduce the risk of severe cardiovascular outcomes, according to reporting by WSJ.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.